Amgen Oncology Pipeline: Investigating Next-Generation Medicines
Learn more about Amgen gastrointestinal oncology clinical trials.
Learn more about Amgen thoracic oncology clinical trials.
Learn more about key clinical trials happening in Amgen oncology.
Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line...
Trial in progress: Phase 3 study of bemarituzumab + mFOLFOX6 versus placebo + mFOLFOX6...
Trial in progress: Phase 1b/3 study of bemarituzumab + mFOLFOX6 + nivolumab...
Phase 2 study of tarlatamab, a DLL3-targeting, half life–extended, bispecific T-cell...
Design and rationale of a phase 1 dose-escalation study of AMG 193...
A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate...
Real-world outcomes of biosimilar bevacizumab-awwb versus reference bevacizumab in patients...
Bone-targeting agent utilization among lung cancer patients with bone metastasis in Taiwan.
Amgen Oncology is advancing all angles of care. Through our mission and our medicines, we're transforming what's possible.